Answer
In the Phase 3 study of Inaqovi in 80 adults with acute myeloid leukaemia, the most common serious adverse reactions were febrile neutropaenia and pneumonia, each occurring in at least 20% of patients.
Sources for this answer
- Inaqovi 35 mg/100 mg film coated tabletsOtsuka Pharmaceuticals (UK) Ltd · emc · SmPC §4.8 Undesirable effects · Version 2Document updated
Sources checked